Science AI Journal
Medicine · Research topic

Open research questions in Pituitary Gland Disorders and Treatments

76 unresolved questions extracted from the limitations and future-work sections of 217 Pituitary Gland Disorders and Treatments papers in our library. Each links back to the study that raised it.

What the literature leaves open

  • The study has a limited sample size, which may have contributed to the lack of statistical significance in the differences between the cabergoline and control groups. The study relies on self-report questionnaires and semi-structured interviews, which may be subject to biases and limitations. The study does not include a longitudinal design, which may limit the ability to assess the temporal relationship between cabergoline treatment and the development of impulse control disorders.

    Impulse control disorders and their relationship with psychopathology in patients treated with cabergoline for hyperprolactinaemia · 2026 · DOI

  • There is a lack of studies evaluating the efficacy of postoperative screening for distress symptom cluster in patients undergoing surgery for PA.

    Postoperative screening for distress symptom cluster in patients with pituitary adenomas: a propensity-score matched outcome analysis · 2026 · DOI

  • CD is a rare and complex disease. Quality-of-life outcomes can be heterogeneous and difficult to predict. There is a need for individualized support and follow-up care after surgery.

    Quality-of-Life Recovery in Cushing’s Disease: A Cluster Analysis · 2026 · DOI

  • Diagnostic delay in men with pituitary adenomas - Limited awareness of sex-related differences in skeletal involvement - Need for gender-specific treatment strategies

    Osteometabolic complications in patients with secreting pituitary adenomas: Is there an impact of gender? · 2026 · DOI

  • Indolent and invasive growth patterns of non-functioning pituitary adenomas. Limited understanding of molecular mechanisms underlying post-surgical progression. Difficulty in stratifying patients according to risk of tumor progression.

    Exploring epigenome-proteome interactions underlying post-surgical progression of non-functioning pituitary adenomas using hypernetwork modelling · 2026 · DOI

  • Profound hyponatremia as the initial presentation of RCC-associated hypopituitarism remains uncommon and may delay diagnosis.

    Hyponatremia as the Initial Presentation of Rathke’s Cleft Cyst-Related Hypopituitarism · 2026 · DOI

  • Future studies should aim to replicate the findings of this study in larger samples and with longer follow-up periods. Future studies should investigate the temporal relationship between cabergoline treatment and the development of impulse control disorders. Future studies should assess the effectiveness of interventions aimed at preventing or treating impulse control disorders in patients with hyperprolactinaemia treated with cabergoline.

    Impulse control disorders and their relationship with psychopathology in patients treated with cabergoline for hyperprolactinaemia · 2026 · DOI

  • However, morphological changes of the PG and PS in the presence of PAs remain incompletely characterized.

    Magnetic resonance imaging-based morphometric differences in the normal pituitary gland with functional and nonfunctional pituitary adenomas · 2026 · DOI

  • Although long-term follow-up data are limited given the rarity of this tumor, recurrence is reported and therefore long-term follow-up is necessary.

    Functional gonadotroph adenomas · 2026 · DOI

  • Given that these tumors are not common, there is limited information available regarding optimal management.

    Functional gonadotroph adenomas · 2026 · DOI

  • Personalized therapeutic strategies for collision tumors of the sellar region have not been established. Future studies should investigate whether tumors with combined ACTH-secreting PitNET and pituicytoma components exhibit different treatment responses to pharmacological therapy (dopamine agonists, somatostatin analogs) or require modified surgical approaches compared to conventional pituitary adenomas.

    Case Report: Rare collision tumors: ACTH-secreting pituitary neuroendocrine tumor and pituicytoma – histopathological and ultrastructural analysis · 2026 · DOI

  • The rarity of ACTH-secreting pituitary neuroendocrine tumor and pituicytoma collision tumors limits the available clinical and pathological data. Systematic case series and registry studies should be established to collect histopathological, immunohistochemical, and clinical outcome data from multiple institutions to better characterize the epidemiology and natural history of these exceptional sellar region collision lesions.

    Case Report: Rare collision tumors: ACTH-secreting pituitary neuroendocrine tumor and pituicytoma – histopathological and ultrastructural analysis · 2026 · DOI

  • Detecting microadenomas, particularly in Cushing disease, remains challenging due to their small size and often subtle imaging findings. Technical challenges limit the use of ultra-high-field 7 T imaging.

    Decoding the sella: a review of MRI in pituitary lesions—from dynamic imaging to artificial intelligence · 2026 · DOI

  • Prospective validation of AI-based radiomics models remains limited. Technical challenges including B1 inhomogeneity and increased specific absorption rate limit the use of ultra-high-field 7 T imaging.

    Decoding the sella: a review of MRI in pituitary lesions—from dynamic imaging to artificial intelligence · 2026 · DOI

  • The heterogeneity of PitNETs. The complexity of lineage classification. The need for a model that can identify regions prioritized for classification.

    Lineage Classification of Pituitary Neuroendocrine Tumors From Whole-Slide Images Using Attention-Guided Graph Representation Learning · 2026 · DOI

  • To evaluate the model on a larger number of cases with multiple synchronous PitNETs of distinct lineages. To compare the model to other state-of-the-art models. To explore the use of the model in other applications, such as informing lineage classification in other types of tumors.

    Lineage Classification of Pituitary Neuroendocrine Tumors From Whole-Slide Images Using Attention-Guided Graph Representation Learning · 2026 · DOI

  • The absence of universally accepted diagnostic criteria for cyclical Cushing's syndrome is a significant gap. The need for longitudinal biochemical surveillance and advanced localization strategies is not well established.

    Cyclical ectopic Cushing’s syndrome due to a mediastinal neuroendocrine tumor: a case-based review · 2026 · DOI

  • Diagnosis and treatment of immature PIT-1 lineage tumors are challenging due to their rarity and aggressive nature. Limited understanding of the clinicopathological features and treatment outcomes of this entity. Need for further research to improve treatment outcomes.

    Clinicopathological features and outcomes of immature PIT-1 lineage tumors: A high-risk pituitary neuroendocrine tumor/pituitary adenoma subtype per WHO 2022 · 2026 · DOI

  • Prospective studies with larger sample sizes are needed to confirm the findings. Further research is needed to identify factors associated with residual disease and recurrence. Development of new treatment strategies is necessary to improve outcomes for immature PIT-1 lineage tumors.

    Clinicopathological features and outcomes of immature PIT-1 lineage tumors: A high-risk pituitary neuroendocrine tumor/pituitary adenoma subtype per WHO 2022 · 2026 · DOI

  • The study is limited by its retrospective design. The sample size is relatively small. The heterogeneity of patient follow-up intervals may introduce variability. The inclusion period spans advances in radiosurgery planning, which might introduce variability in dosimetry.

    LINAC Stereotactic Radiosurgery for Functional Pituitary Adenomas Following Recurrence After Transsphenoidal Surgery: Tumor Control and Endocrine Outcomes in a Single-center Series · 2026 · DOI

  • Further studies are needed to fully understand the effects of LINAC SRS on functional pituitary adenomas. The study's results can inform the development of more effective treatment strategies for patients with functional pituitary adenomas. Long-term follow-up studies are needed to assess the durability of tumor control and endocrine outcomes.

    LINAC Stereotactic Radiosurgery for Functional Pituitary Adenomas Following Recurrence After Transsphenoidal Surgery: Tumor Control and Endocrine Outcomes in a Single-center Series · 2026 · DOI

  • Trial registration numberChiCTR2400081636 STRENGTHS AND LIMITATIONS OF THIS STUDYO_ST_ABSStrengthC_ST_ABS[tpltrtarr] This study proposes an integrated, clinically applicable preoperative strategy that combines imaging-based prediction with selective cerebrospinal fluid cell-free DNA analysis to identify papillary craniopharyngioma (PCP) prior to surgery.

    Study protocol for preoperative classification using integrated screening and short-course neoadjuvant BRAF/MEK inhibition in newly diagnosed papillary craniopharyngioma (the PRECISE-PCP study): a prospective single-arm study · 2026 · DOI

  • The coexistence of exogenous and endogenous Cushing's syndrome is very rare and may lead to delayed diagnosis and management. There are no data on the incidence of exogenous Cushing's syndrome.

    Is it Possible to Have Coexisting Exogenous and Endogenous Cushing's Syndrome? · 2026 · DOI

  • The study notes that publication bias was not formally assessed with funnel plots due to the small number and heterogeneity of included studies. The study also notes that the lack of prospective studies limits the interpretability of the results.

    Pituitary adenoma and intracerebral aneurysms: case series, systematic review and meta-analysis · 2026 · DOI

  • Future studies should investigate the underlying mechanisms of the association between IAs and PAs. Future studies should explore the clinical implications of the study's findings. Future studies should aim to develop clinical guidelines for the management of PA patients with IAs.

    Pituitary adenoma and intracerebral aneurysms: case series, systematic review and meta-analysis · 2026 · DOI

Most-cited papers in Pituitary Gland Disorders and Treatments

Most recent work

Find a gap in your own Pituitary Gland Disorders and Treatments sub-topic

This page shows what the Pituitary Gland Disorders and Treatments literature already flags as unresolved. To narrow it to your specific question, run the guided finder — it searches the gap library on demand and checks candidates against 250M+ OpenAlex works.

Open the Research Gap Finder →

Related topics in Medicine

Substance Abuse Treatment and Outcomes
1,213 open questions
Artificial Intelligence in Healthcare and Education
1,153 open questions
Physical Activity and Health
718 open questions
Dementia and Cognitive Impairment Research
565 open questions
Attention Deficit Hyperactivity Disorder
544 open questions
Smoking Behavior and Cessation
532 open questions
Innovations in Medical Education
480 open questions
HIV/AIDS Research and Interventions
472 open questions
76 open questions have been extracted from the limitations and future-work passages of 217 Pituitary Gland Disorders and Treatments papers in our library. Each one below links back to the study that raised it, so you can read the original claim in context.

Tools for your next paper

Gaps & Literature SearchFind open questions in any field — 120,000+ open gaps mined from our own library.Pre-CheckIs your paper ready? A Tier 1–5 acceptance probability in seconds.Journal FinderA ranked shortlist of target journals from a 17,500-venue index.Duplicate Publication CheckerCheck prior-publication & salami-slicing risk across 8 sources.Citation GeneratorFreeA DOI or title → APA, MLA, Vancouver, Chicago, BibTeX, RIS. No signup.Graphical Abstract MakerFreeTurn your findings into a colorblind-safe graphical abstract.

Compare the category — Honest roundups of the AI research tools, ours listed alongside the alternatives.

Command palette

Jump anywhere, run any action.